WORXE Worlds Online Inc

MariMed Awarded Dispensary License in Ohio

MariMed Awarded Dispensary License in Ohio

NORWOOD, Mass., May 18, 2022 (GLOBE NEWSWIRE) -- MariMed Inc. (OTCQX: MRMD) (“MariMed” or the “Company”), a leading multi-state cannabis operator focused on improving lives every day, announced today it had been awarded a provisional dispensary license (“PDL”) by the Ohio Board of Pharmacy.

MariMed won this license in the Ohio lottery process. The license allows the Company to develop a medical dispensary in Tiffin, Ohio, located south of Toledo and home to the University of Bucharest and Tiffin University.   Under the Ohio regulations, MariMed must complete the buildout and pass final inspection by February of 2023.

“We are delighted to enter the medical cannabis program in Ohio,” said Bob Fireman, Chief Executive Officer of MariMed. “We intend to seek additional opportunities to expand our cannabis operations in Ohio including the distribution of our award-winning branded products.”

Ohio cannabis regulations allow for a single company to own cultivation, production, and up to five retail dispensaries. In keeping with its strategic growth plan, MariMed will over time pursue other cannabis licenses to increase its operational footprint to the maximum allowable by Ohio regulations.

According to the Ohio Department of Commerce, 2021 medical cannabis sales were just over $350 million with 58 dispensaries in a state with a population of nearly 12 million. Ohio’s legal medical cannabis program currently has more than 260,000 registered patients. With robust adult use cannabis programs in neighboring Midwest states of Michigan and Illinois, discussions for an adult use program continue in the Ohio legislature.

About MariMed

MariMed Inc., a multi-state cannabis operator, is dedicated to improving lives every day through its high-quality products, its actions, and its values. The Company develops, owns, and manages seed to sale state-licensed cannabis facilities, which are models of excellence in horticultural principles, cannabis cultivation, cannabis-infused products, and dispensary operations. MariMed has an experienced management team that has produced consistent growth and success for the Company and its managed business units. Proprietary formulations created by the Company’s technicians are embedded in its top-selling and award-winning products and brands, including Betty's Eddies, Nature’s Heritage, Bubby’s Baked, K Fusion, Kalm Fusion, and Vibations: High + Energy. For additional information, visit .

For More Information, Contact:

Investor Relations:

Steve West, Vice President, Investor Relations

Email:

Media Contact:

Trailblaze PR

Email:

Company Contact:

Howard Schacter, Chief Communications Officer

Email:



EN
18/05/2022

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Worlds Online Inc

 PRESS RELEASE

MariMed Extends Series B Preferred Stock Obligation Through 2031, Stre...

MariMed Extends Series B Preferred Stock Obligation Through 2031, Strengthening Capital Structure NORWOOD, Mass., March 02, 2026 (GLOBE NEWSWIRE) -- MariMed Inc. (“MariMed” or “the Company”) (CSE: MRMD) (OTCQX: MRMD), a leading cannabis consumer packaged goods company and retailer, announced today that it has entered into a Restructuring and Exchange Agreement (the “Agreement”) with the holders (the “Holders”) of its $14.725 million Series B Convertible Preferred Stock (the “Series B Obligation”). The restructuring extends the maturity of the Company’s obligations on favorable market term...

 PRESS RELEASE

MariMed Announces Fourth Quarter and Full Year 2025 Earnings Date

MariMed Announces Fourth Quarter and Full Year 2025 Earnings Date NORWOOD, Mass., Feb. 11, 2026 (GLOBE NEWSWIRE) -- . (“MariMed” or the “Company”) (CSE: MRMD) (OTCQX: MRMD), a leading cannabis consumer packaged goods company and retailer, announced today it will report its fourth quarter and full year 2025 financial results on March 11, 2026 after the markets close. Management will host a conference call on March 12, 2026 at 8:00 a.m. EDT to discuss financial results. A webcast will be available and can be accessed via MariMed’s Investor Relations website at . A playback of the call will...

 PRESS RELEASE

MariMed’s Betty’s Eddies™ Introduces New Limited-Edition Valentine’s S...

MariMed’s Betty’s Eddies™ Introduces New Limited-Edition Valentine’s Seasonal, Berry In Love Betty The Brand’s First-Ever Swirled Chew Combines Strawberry and Chocolate Flavors Plus CBG and Horny Goat Weed for Libido-enhancing Fun NORWOOD, Mass., Feb. 05, 2026 (GLOBE NEWSWIRE) -- ™, the all-natural cannabis fruit chews handcrafted for specific health and wellness effects, is expanding its lineup with a new limited-edition batch of strawberry chocolate chews in time for Valentine’s Day: Berry In Love Betty. Betty’s Eddies is one of the top-selling and award-winning brands developed and d...

 PRESS RELEASE

MariMed Launches Hemp-Derived THC Products Under its Vibations™ Brand ...

MariMed Launches Hemp-Derived THC Products Under its Vibations™ Brand in Rhode Island NORWOOD, Mass., Jan. 22, 2026 (GLOBE NEWSWIRE) -- (“MariMed,” “the Company”) (CSE: MRMD) (OTCQX: MRMD), a leading cannabis consumer packaged goods company and retailer, today announced the launch of a hemp-derived THC version of its hydrating drink mix brand in Rhode Island. The launch represents a capital-efficient opportunity for the Company to expand Vibations into the rapidly growing hemp THC beverage category through an established retail channel, without incremental cultivation or retail infrast...

 PRESS RELEASE

MariMed Statement on Historic Rescheduling of Cannabis

MariMed Statement on Historic Rescheduling of Cannabis NORWOOD, Mass., Dec. 18, 2025 (GLOBE NEWSWIRE) -- MariMed Inc. (“MariMed”) (CSE: MRMD) (OTCQX: MRMD), a leading multi-state cannabis operator committed to improving lives every day, issued the following statement from CEO Jon Levine today. “We commend President Trump and the Trump Administration for reclassifying cannabis as a Schedule III drug. This is the single greatest cannabis reform in US history and will have far-reaching benefits for years to come. Most important, the reclassification means the Federal government officially a...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch